Addex Therapeutics (ADXN) Set to Announce Quarterly Earnings on Monday

Addex Therapeutics (NASDAQ:ADXN) is set to announce its earnings results before the market opens on Monday, November 11th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Addex Therapeutics (NASDAQ:ADXN) last released its earnings results on Monday, September 30th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($1.70). Addex Therapeutics had a negative return on equity of 190.29% and a net margin of 463.11%. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.26 million. On average, analysts expect Addex Therapeutics to post $10 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Addex Therapeutics Trading Up 9.7 %

NASDAQ ADXN opened at $10.70 on Monday. The business’s 50 day moving average is $10.28 and its two-hundred day moving average is $9.48. Addex Therapeutics has a 12-month low of $5.00 and a 12-month high of $27.90. The stock has a market capitalization of $11.34 million, a price-to-earnings ratio of -6.52 and a beta of 1.78.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Addex Therapeutics in a report on Wednesday, October 2nd.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.